Dr. Krambeck investigates efficacy of Trilogy and ShockPulse-SE lithotripters

“You have tradeoffs with every device that you use,” says Amy E. Krambeck, MD.

In this episode, Urology Times® Managing Editor Ben Saylor spoke with Amy E. Krambeck, MD. She discusses the recent Journal of Endourology study, "Multi-institutional prospective randomized control trial of novel intracorporeal lithotripters: ShockPulse-SE vs Trilogy trial," for which she served as senior author. Krambeck is a professor of urology at Northwestern University Feinberg School of Medicine in Chicago, Illinois.